【摘要】 目的观察吸入布地奈德治疗慢性阻塞性肺疾病(COPD)急性加重期患者的临床疗效。方法将50例COPD急性加重期患者随机分为治疗组(25例)和对照组(25例)。两组均在常规治疗基础上每日3次雾化吸入布地奈德,治疗组每次2 mg,对照组每次1 mg。对比治疗7 d后患者症状缓解情况及第1秒钟用力呼吸容积(FEV1)、FEV1占预计值(FEV1%)、FEV1/FVC%的变化。结果治疗组临床缓解有效率明显高于对照组,P<0.05,治疗组FEV1和FEV1/FVC%较对照组明显改善(P<0.05)。结论每日吸入6 mg布地奈德对COPD急性加重期有更好的疗效,能显著缓解胸闷、喘息、气短症状,有效改善肺功能。更多还原

【Abstract】 Objective To observe the effect of budesonide inhalation aerosol in the treatment of the acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods Totally 50 subjects with AECOPD were randomly divided into two groups.All patients were treated with the base of routine therapy and budesonide inhalation aerosol,the treatment group’s dosage was 2 mg three times a day,the comparative group’s dosage was 1 mg three times a day.Compare the difference of two groups at symptoms defusing remission,FEV1,FEV1% and FEV1/FVC% before and after the 7 days’ therapy.Results The clinical remission rate of the treatment group was significantly higher than the comparative group(P<0.05),FEV1 and FVC of the treatment group were significantly improved(P<0.01).Conclusion Budesonide inhalation aerosol can significantly relieve chest tightness,wheezing,shortness of breath symptoms,effective in improving lung function.更多还原